Nexstim
Focussing on strategic prioritiesBonesupport
Cementing the foundations for growthHutchison China MediTech
A wealth of opportunity for surufatinibFutura Medical
MED3000 European regulatory pathway is clearerBerGenBio
Focused on second-line NSCLC and AMLMereo BioPharma
Funding deals worth up to $33m announcedScancell
US IND for SCIB1 gives Phase II study the green lightScancell
Interim results show encouraging progressHutchison China MediTech
2020 set to be the “breakthrough” yearHutchison China MediTech
$110m raised through ADS public offer